Sugi Predict

Sugi Predict / Compounds / SCHEMBL57438

SCHEMBL57438

SCHEMBL57438

Cc1ccc(S(=O)(=O)OCCOC(C)C)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.45
▸ CA9 Q16790 3/20 0.45
▸ CA1 P00915 2/20 0.45
▸ CYP3A4 P08684 3/20 0.43
▸ ALDH1A1 P00352 8/20 0.41
▸ GAA P10253 3/20 0.41
▸ STAT3 P40763 1/20 0.40
▸ GBA1 P04062 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ CA2 P00918 2/20 0.38
▸ CA3 P07451 1/20 0.38
▸ CA6 P23280 1/20 0.38
▸ CA5A P35218 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CA5B Q9Y2D0 1/20 0.38
▸ VDR P11473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2564478 0.90 CYP3A4 (0.46) CA12CA9CA1CYP3A4ALDH1A1
SCHEMBL241884 0.87 CA1 (0.52) CA12CA9CA1CYP3A4ALDH1A1
SCHEMBL19768835 0.87 CA9 (0.43) CA12CA9CA1CYP3A4ALDH1A1
SCHEMBL7809011 0.85 CA9 (0.45) CA12CA9CA1CYP3A4ALDH1A1
SCHEMBL23160909 0.85 CA9 (0.45) CA12CA9CA1CYP3A4ALDH1A1
SCHEMBL6929762 0.85 ALDH1A1 (0.43) CA12CA9CA1ALDH1A1GAA
SCHEMBL17967399 0.85 CA12 (0.44) CA12CA9CA1CYP3A4ALDH1A1
SCHEMBL9019023 0.85 CA12 (0.40) CA12CA9CA1CYP3A4ALDH1A1
SCHEMBL9019029 0.85 CA12 (0.40) CA12CA9CA1CYP3A4ALDH1A1
SCHEMBL14795272 0.84 CA1 (0.41) CA12CA9CA1CYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12465643-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-11-11 — — US disclosed
US-20250319187-A1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2025-10-16 — — US disclosed
US-12409225-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-09-09 — — US disclosed
US-12403196-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-09-02 — — US disclosed
US-20250255964-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-08-14 — — US disclosed
US-20250242029-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT 2025-07-31 — — US disclosed
US-20250195662-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-06-19 — — US disclosed
US-20250195521-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS Revolution Medicines, Inc. 2025-06-19 — — US disclosed
US-20250186590-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-06-12 — — US disclosed
US-12280113-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-04-22 — — US disclosed
EP-2046755-A2 PYRAZOLES AS GLUCOKINASE ACTIVATORS F. Hoffmann-Roche AG (CH) 2009-04-15 — — EP disclosed
EP-1968940-A1 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS Novartis AG (CH) 2008-09-17 — — EP disclosed
WO-2008012227-A2 PYRAZOLES AS GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2008-01-31 — — WO disclosed
US-20080021032-A1 Pyrazole glucokinase activators BERTHEL STEVEN JOSEPH 2008-01-24 — — US disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 — — WO disclosed
US-5384319-A Interleukin inhibitors; analgesics CIBA-GEIGY CORPORATION (US) 1995-01-24 — — US disclosed
EP-0606049-A1 Aminoalkylphenyl compounds CIBA-GEIGY AG (CH) 1994-07-13 — — EP disclosed
US-5286728-A Amino-substituted piperazine derivatives CIBA-GEIGY CORPORATION (US) 1994-02-15 — — US disclosed
EP-0524146-A1 Aminosubstituted Piperazinederivatives CIBA-GEIGY AG (CH) 1993-01-20 — — EP disclosed
US-4070179-A Plant growth regulation with N-(2-alkoxy-ethyl)-N-chloroacetyl-2,3,6-trimethyl-anilines CIBA-GEIGY CORPORATION (US) 1978-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195662-A1 RAS INHIBITORS KRAS, NRAS, HRAS CA12 4023/4885CA9 3085/4885CA1 4685/4885
US-20250186590-A1 RAS INHIBITORS KRAS, NRAS, HRAS CA12 4023/4885CA9 3085/4885CA1 4685/4885
US-20250319187-A1 RAS INHIBITORS KRAS, NRAS, HRAS CA12 4023/4885CA9 3085/4885CA1 4685/4885
US-20250195521-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS SOS1, PPM1D, PTPN1 CA12 4480/4885CA9 3507/4885CA1 4247/4885
US-20250255964-A1 RAS INHIBITORS KRAS, NRAS, HRAS CA12 4023/4885CA9 3085/4885CA1 4685/4885
US-12403196-B2 Ras inhibitors KRAS, NRAS, HRAS CA12 4023/4885CA9 3085/4885CA1 4685/4885
US-12465643-B2 Ras inhibitors KRAS, NRAS, HRAS CA12 4023/4885CA9 3085/4885CA1 4685/4885
US-20250242029-A1 RAS INHIBITORS KRAS, NRAS, HRAS CA12 4023/4885CA9 3085/4885CA1 4685/4885
US-12280113-B2 Ras inhibitors KRAS, NRAS, HRAS CA12 4023/4885CA9 3085/4885CA1 4685/4885
US-20080021032-A1 Pyrazole glucokinase activators GCKR, GCK, GALK1 CA12 4798/4885CA9 4098/4885CA1 4612/4885
US-12409225-B2 Ras inhibitors KRAS, NRAS, HRAS CA12 4023/4885CA9 3085/4885CA1 4685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.